Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
3.965
+0.065 (1.67%)
May 14, 2025, 4:00 PM - Market closed
Astria Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
78
Market Cap
223.76M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATXS News
- 23 hours ago - Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
- 11 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology - Business Wire
- 14 days ago - Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference - Business Wire
- 2 months ago - Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Business Wire
- 2 months ago - Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire
- 2 months ago - Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire
- 2 months ago - Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire